These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17425633)

  • 21. Improve efficiency and reduce bias of Cox regression models for two-stage randomization designs using auxiliary covariates.
    Yang X; Zhou Y
    Stat Med; 2017 May; 36(11):1683-1695. PubMed ID: 28183157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simple approach to power and sample size calculations in logistic regression and Cox regression models.
    Vaeth M; Skovlund E
    Stat Med; 2004 Jun; 23(11):1781-92. PubMed ID: 15160408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Mizon-Richard encompassing test for the Cox and Aalen additive hazards models.
    Martinussen T; Aalen OO; Scheike TH
    Biometrics; 2008 Mar; 64(1):164-71. PubMed ID: 17608786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival model predictive accuracy and ROC curves.
    Heagerty PJ; Zheng Y
    Biometrics; 2005 Mar; 61(1):92-105. PubMed ID: 15737082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multivariate time-to-event analysis of multiple adverse events of drugs in integrated analyses.
    Güttner A; Kübler J; Pigeot I
    Stat Med; 2007 Mar; 26(7):1518-31. PubMed ID: 16903003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tests for treatment group differences in the hazards for survival, before and after the occurrence of an intermediate event.
    Bebchuk JD; Betensky RA
    Stat Med; 2005 Feb; 24(3):359-78. PubMed ID: 15568187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Misspecified regression model for the subdistribution hazard of a competing risk.
    Latouche A; Boisson V; Chevret S; Porcher R
    Stat Med; 2007 Feb; 26(5):965-74. PubMed ID: 16755533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inference for the proportional hazards model with misclassified discrete-valued covariates.
    Zucker DM; Spiegelman D
    Biometrics; 2004 Jun; 60(2):324-34. PubMed ID: 15180657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Weighted log-rank statistic to compare shared-path adaptive treatment strategies.
    Kidwell KM; Wahed AS
    Biostatistics; 2013 Apr; 14(2):299-312. PubMed ID: 23178734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudo cluster randomization: a treatment allocation method to minimize contamination and selection bias.
    Borm GF; Melis RJ; Teerenstra S; Peer PG
    Stat Med; 2005 Dec; 24(23):3535-47. PubMed ID: 16007575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A SAS macro for constrained randomization of group-randomized designs.
    Chaudhary MA; Moulton LH
    Comput Methods Programs Biomed; 2006 Sep; 83(3):205-10. PubMed ID: 16870302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A generalized log-rank test for interval-censored failure time data via multiple imputation.
    Huang J; Lee C; Yu Q
    Stat Med; 2008 Jul; 27(17):3217-26. PubMed ID: 18254128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five interval estimators for proportion ratio under a stratified randomized clinical trial with noncompliance.
    Lui KJ; Chang KC
    Biom J; 2007 Aug; 49(4):613-26. PubMed ID: 17634977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statistical comparison of random allocation methods in cancer clinical trials.
    Hagino A; Hamada C; Yoshimura I; Ohashi Y; Sakamoto J; Nakazato H
    Control Clin Trials; 2004 Dec; 25(6):572-84. PubMed ID: 15588744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A two-stage design for choosing among several experimental treatments and a control in clinical trials.
    Thall PF; Simon R; Ellenberg SS
    Biometrics; 1989 Jun; 45(2):537-47. PubMed ID: 2765637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cluster without fluster: The effect of correlated outcomes on inference in randomized clinical trials.
    Proschan M; Follmann D
    Stat Med; 2008 Mar; 27(6):795-809. PubMed ID: 17594680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment allocation for nonlinear models in clinical trials: the logistic model.
    Begg CB; Kalish LA
    Biometrics; 1984 Jun; 40(2):409-20. PubMed ID: 6487725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blinded assessment of treatment effects utilizing information about the randomization block length.
    Miller F; Friede T; Kieser M
    Stat Med; 2009 May; 28(12):1690-706. PubMed ID: 19340815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interim analysis on survival data: its potential bias and how to repair it.
    van Houwelingen HC; van de Velde CJ; Stijnen T
    Stat Med; 2005 Sep; 24(18):2823-35. PubMed ID: 16025546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.